Nuclear export signal within CALM is necessary for CALM-AF10-induced leukemia

Mai Suzuki, Kazutsune Yamagata, Mika Shino, Yukiko Aikawa, Koichi Akashi, Toshio Watanabe and Issay Kitabayashi

Division of Hematological Malignancy, National Cancer Center Research Institute, Tokyo; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka; Department of Biological Science, Graduate School of Humanities and Sciences, Nara Women’s University, Nara, Japan

Key words
AF10, chromosome translocation, histone modification, leukemia, nuclear export signal

Correspondence
Issay Kitabayashi, Division of Hematological Malignancy, National Cancer Center Research Institute, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Tel: +81-3-3542-2511; Fax: +81-3-3542-0688;
E-mail: ikitabay@ncc.go.jp

Funding Information
Ministry of Education, Culture, Sports, Science, and Technology. National Cancer Center Research and Development Fund. Naito Foundation. Cosmetology Research Foundation. Nara Women’s University Intramural Grant for Project Research.

Received September 16, 2013; Revised December 5, 2013; Accepted December 30, 2013

The CALM–AF10 fusion gene, which results from a t(10;11) translocation, is found in a variety of hematopoietic malignancies. Certain HOXA cluster genes and MEIS1 genes are upregulated in patients and mouse models that express CALM-AF10. Wild-type clathrin assembly lymphoid myeloid leukemia protein (CALM) primarily localizes in a diffuse pattern within the cytoplasm, whereas AF10 localizes in the nucleus; however, it is not clear where CALM-AF10 acts to induce leukemia. To investigate the influence of localization on leukemogenesis involving CALM-AF10, we determined the nuclear export signal (NES) within CALM that is necessary and sufficient for cytoplasmic localization of CALM-AF10. Mutations in the NES eliminated the capacity of CALM-AF10 to immortalize murine bone-marrow cells in vitro and to promote development of acute myeloid leukemia in mouse models. Furthermore, a fusion of AF10 with the minimal NES can immortalize bone-marrow cells and induce leukemia in mice. These results suggest that during leukemogenesis, CALM-AF10 plays its critical roles in the cytoplasm.

The chromosome translocation t(10;11)(p13;q14), found in T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia (AML) and malignant lymphomas, results in the fusion of the clathrin assembly lymphoid myeloid leukemia protein (CALM) and AF10. The CALM–AF10 fusion protein consists of almost all CALM and AF10 proteins, with the exception of one or two plant homeodomain (PHD). AF10, also known as MLLT10, interacts with the transcription factor Ikaros and H3K4me3 through its octapeptide motif–leucine zipper (OM-LZ) region and PHD domains, respectively. In both mice and humans, CALM-AF10 upregulates certain HOXA cluster genes (HOXA5, HOXA7, HOXA9 and HOXA10) and MEIS1. HOXa5 upregulation, which is critical for CALM-AF10-induced leukemogenesis, is mediated by an interaction between the AF10 OM-LZ region and the histone methyltransferase DOT1L, resulting in H3K79 hypermethylation at the Hoxa5 locus. These findings suggest that CALM-AF10 might function in the nucleus.

The CALM protein shuttles between the cytoplasm and the nucleus under the control of a CRM1-dependent nuclear export signal (NES). In contrast to AF10, which localizes in the nucleus, CALM-AF10 primarily localizes in the cytoplasm. Other fusion partners of AF10 in acute myeloid and lymphoid leukemias include MLL, DDX3 and hnRNPH1. MLL and hnRNPH1 primarily localize in the nucleus whereas DDX3, like CALM, is mostly distributed throughout the cytoplasm. These observations prompted us to investigate whether CALM-AF10 exerts its function in the nucleus or the cytoplasm. We found that mutant CALM-AF10 lacking the NES localized in the nucleus and lost its ability to induce leukemia in mice. Conversely, a fusion consisting of the minimal NES and AF10 localized in the cytoplasm and induced leukemia. These results indicate that the cytoplasmic location of CALM-AF10 is critical for its role in leukemogenesis.

Materials and Methods

Generation of CALM-AF10 mutant constructs. Plasmid encoding pCDNA3β-FLAG-CALM-AF10 was a gift from Y. Zhang (Department of Biochemistry and Biophysics, University of North Carolina). Plasmid encoding the NES-deficient mutant FLAG-CALM NES4A-AF10 and FLAG-CALM NES4A were generated by introducing four point mutations into the CALM NES sequence by inverse PCR using a site-specific mutagenesis kit (Toyobo, Osaka, Japan). Specifically, leucine (L)-544, L-547, L-551 and isoleucine (I)-553 in the putative NES sequence within CALM-AF10 were replaced by alanine (A), using the following primers: L544A, 5’-GCAGCACAATTCTTGG

© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cancer Sci | March 2014 | vol. 105 | no. 3 | 315–323
GACAATTCGGC-3', and 5'-AGATGAATCCTAGATATCGAG TACT-3', L547A, 5'-GGCTGGGCAATCTTGCGCTGATGAA AT-3', and 5'-GTGCTGGGCAATCTTGCGCTGATGAATC-3'. L551A, 5'-GCTGCGCATAAGGAAATGGAACCACTAAG-3', and 5'-ATT GCCCAACGCTTGGCTGCAGATGAATCCAAGTCA-3'. All mutations were confirmed by DNA sequencing. The AF10 sequence encoding amino acids 81–1027 (mAF10) was amplified by PCR and cloned into pcDNA3-FLAG. To generate the fusion of the minimal NES with AF10, NES1 (amino acids 543–554) or NES2 (amino acids 539–558) within CALM was generated by PCR amplification using FLAG-CALM-AF10 as a template, and then cloned into pcDNA3-FLAG-mAF10. The pMY-IG-FLAG-CALM-AF10-IRES-GFP, pMY-IG-FLAG-mAF10-IRES-GFP, and pMY-IG-FLAG-NES2-AF10-IRES-GFP constructs were generated by inserting the corresponding cDNA into the pMY-IG-IRES-GFP vector. 

Cell culture and transfection. COS-7 cells were maintained in DMEM supplemented with 10% FBS, 100 μg/mL penicillin, and 2 mM L-glutamine at 37°C in a humidified 5% CO2 incubator. COS-7 cells were transfected with pcDNA3-FLAG constructs using the Effectene Transfection Reagent (Qiagen, Hilden, Germany). COS-7 cells were transfected with pcDNA3-FLAG constructs using the Effectene Transfection Reagent (Qiagen, Hilden, Germany). COS-7 cells were transfected with pcDNA3-FLAG constructs using the Effectene Transfection Reagent (Qiagen, Hilden, Germany). 

Immunofluorescence analysis. COS-7 cells transfected with pcDNA3-FLAG constructs were fixed with 3.7% formaldehyde in PBS and examined by immunofluorescence staining with anti-FLAG M2 monoclonal antibody (Sigma-Aldrich, St. Louis, MO, USA), followed by secondary Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA). Stained cells were mounted in VECTASHIELD mounting medium and observed using a BX50 fluorescence microscope (Olympus, Tokyo, Japan). Cytospins of murine bone-marrow cells transduced with pMY-IG-IRES-GFP viral constructs encoding FLAG-CALM-AF10, FLAG-CALM-NES4A-AF10, FLAG-NES2-AF10, or FLAG-mAF10 were fixed with 4% paraformaldehyde and stained with anti-FLAG M2 monoclonal antibody (Sigma-Aldrich) and anti-KMT4 monoclonal antibody (Sigma-Aldrich) and Alexa Fluor 488-conjugated goat anti-rabbit IgG (Invitrogen), respectively. Stained bone-marrow cells were mounted in VECTASHIELD mounting medium with DAPI (Vector Laboratories, Burlingame, CA, USA) or Prolong Gold (Invitrogen) and observed under a BZ-9000 fluorescence microscope (Keyence Corporation, Osaka, Japan) or a Fluoview FV10i confocal laser scanning microscopy (Olympus). 

Retroviral infection and bone-marrow transplantation. C57BL/6 mice were purchased from CLEA Japan (Tokyo, Japan). All mouse experiments were approved by the National Cancer Center Animal Ethics Committee and performed in accordance with the institutional guidelines. The pMY-IG-IRES-GFP constructs encoding FLAG-CALM-AF10, FLAG-CALM-NES4A-AF10, FLAG-NES2-AF10, or FLAG-mAF10 were transfected into PLAT-E cells using the GeneJuice transfection reagent (Novagen, Nottingham, UK), and retrovirus supernatants were collected 48 h after transfection. C-kit+ cells (1 × 106 cells), selected from murine total bone-marrow cells using CD117 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany), were incubated with the retrovirus and RetroNectin (Takara Bio, Madison, WI, USA) for 24 h in StemPro-34 SFM medium (Invitrogen) containing cytokines (20 ng/mL SCF, 10 ng/mL IL-6 and 10 ng/mL IL-3). The transduced donor bone-marrow cells were then transplanted into lethally irradiated (9.5 Gy) 7–8-week-old female C57BL/6J recipient mice by intravenous injection. For secondary transplants, bone-marrow cells from the primary leukemia mice were intravenously injected into sublethally irradiated (6 Gy) female C57BL/6J mice. 

Serial-replating assay. Bone-marrow cells transduced with pMY-IG-IRES-GFP constructs encoding FLAG-CALM-AF10, FLAG-CALM-NES4A-AF10, FLAG-NES2-AF10, or FLAG-mAF10 were cultured for 3 days in methylcellulose medium (MethoCult M3234; StemCell Technologies, Vancouver, Canada) supplemented with murine SCF, IL-3, and GM-CSF. The GFP+ cells in methylcellulose medium were then sorted using a JSAN cell sorter (Bay Bioscience, Kobe, Japan) and replated every 3–4 days in methylcellulose medium; colonies and cells were counted at each passage. Cells from the second-round and fifth-round colonies were harvested and analyzed by real-time PCR (RT-PCR). 

Real-time-PCR analysis. Total RNA from reimplating colonies was purified using an RNeasy Mini Kit (Qiagen). Purified RNA was reverse-transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR was performed using the 7500 Fast Real-time PCR System (Applied Biosystems) using the FastStart Universal Probe Master with ROX (Roche, Basel, Switzerland) and the following TaqMan probes (Applied Biosystems): Hoxa5 (Mm00421338_s1), Hoxa7 (Mm00657963_m1), Hoxa9 (Mm00439364_m1), Hoxa10 (Mm00433966_m1), and Meis1 (Mm00487664_m1). The relative expression levels of these genes were normalized against the level of Actb (Mm00607939_s1). 

Flow-cytometry analysis. Bone-marrow cells from leukemia mice were pre-incubated with rat IgG (Sigma-Aldrich), and then incubated on ice with the appropriate staining reagents: anti-CD115(CSF1R)-PE (eBioscience, San Diego, CA, USA), anti-Mac-1(M1/70)-PE-Cy7 (eBioscience), anti-Gr-1(RB6-8C5)-APC (BD Pharmingen, San Diego, CA, USA) and anti-c-Kit(2B8)-APC-eF780 (eBioscience). FACs analysis and cell sorting were performed using the JSAN cell sorter and the results were analyzed using the FLOWJO software (Tree Star, Standford, CA, USA). 

Results 

The nuclear export signal within CALM is required for cytoplasmic localization of CALM-AF10. To investigate the role of subcellular localization of CALM-AF10 in leukemogenesis, we focused on the NES within the CALM portion of the fusion protein (amino acids 543–554 of CALM). (6) We generated NES-deficient mutants CALM-NES4A-AF10 and CALM-NES4A-AF10 in which leucine-544, leucine-547, leucine-551 and isoleucine-553 in the putative NES region within CALM were substituted with alanines (NES4A) (Fig. 1a). Expression vectors for FLAG-tagged CALM-AF10, CALM, CALM-NES4A-AF10, CALM-NES4A-AF10, and mAF10 (the AF10 portion of CALM-AF10) were transiently transfected into COS-7 cells. Immunofluorescence analysis revealed that CALM and CALM-AF10 primarily localized in the cytoplasm, whereas mAF10 and the NES mutants CALM-NES4A-AF10 and CALM-NES4A-AF10 localized in the nucleus (Fig. 1b,c). 

To determine the minimal NES, two sequences, NES1 (aa. 543–554) and NES2 (aa. 539–558), were fused to AF10 (Fig. 1a,b). As with mAF10, NES1-AF10 was in the nucleus; by contrast, NES2-AF10 was in the cytoplasm (Fig. 1d). The same results were obtained when these fusion proteins were transfected into murine hematopoietic progenitor cells by retro-
Fig. 1. The NES region within clathrin assembly lymphoid myeloid leukemia protein (CALM) is necessary for cytoplasmic localization. (a) Schematic representations of CALM, AF10, CALM-AF10 and mutant proteins. FLAG-CALM NES4A-AF10 and FLAG-CALM NES4A were generated by alanine substitution of three leucine residues and one isoleucine residue in the putative CALM NES (red). FLAG-NES1-AF10 and FLAG-NES2-AF10 mutants were constructed by fusion of the NES sequences of CALM to the AF10 portion of CALM-AF10. (b) Diagrams of the plasmid constructs used in transfection experiments. (c) Subcellular distribution of CALM-AF10 and the NES point mutations FLAG-CALM-AF10, FLAG-CALM, FLAG-CALM NES4A-AF10, FLAG-CALM NES4A, and FLAG-NES1-AF10, FLAG-NES2-AF10 and FLAG-mAF10 in COS-7 cells. Transfected cells were stained with anti-FLAG antibody (green) and observed by fluorescence microscopy. (d) Population of cells expressing transduced genes in the nucleus and cytoplasm shown in (c). (e) Subcellular distribution of CALM-AF10 and NES mutation proteins in murine bone-marrow cells. Transduced cells were stained with anti-FLAG antibody (red) and observed by fluorescence microscopy. (f) Population of cells expressing transduced genes in the nucleus and the cytoplasm shown in (e). Nuclei were stained with DAPI (blue) and observed by fluorescence microscopy. The scale bar represents 20 μm in (c) and 10 μm in (e). ANTH, AP180 N-terminal homology domain binding phosphatidylinositol 4,5-bisphosphate (PIP2); DIF and DPF, motifs interacts with AP-2; NPF, a motif interacts with the EH (Eps15 homology) domain; CBS-I and -II, putative type I and II clathrin-binding sequences; NES, nuclear export signal; PHD Type1 and 2, plant homeodomain zinc finger domains; NLS, nuclear localization signal; AT-hook, DNA-binding protein motif; OMLZ, octapeptide motif-leucine zipper domain; Q-rich, glutamine-rich region.
Fig. 2. The nuclear export signal within clathrin assembly lymphoid myeloid leukemia protein (CALM) is critical for in vitro immortalization of cells by CALM-AF10. (a) Serial colony-replating assays of murine bone-marrow cells transduced with FLAG-tagged wild-type and mutant CALM-AF10. In each round of replating, $3 \times 10^5$ transduced bone-marrow cells were plated. Bars represent the numbers of colonies. (b) Hoxa cluster and Meis1 expression in cells transduced with wild-type or mutant CALM-AF10 in vitro. RNA transcripts were analyzed by real-time PCR of murine bone-marrow cells transduced with wild-type and mutant CALM-AF10. Expression levels of Hoxa5, Hoxa7, Hoxa9, Hoxa10 and Meis1 were normalized against Actb expression and compared with the levels in vector-transfected whole bone-marrow cells. Data are shown as means ± SEM from three independent samples. *P < 0.05; **P < 0.01. (vs normal bone-marrow cells). CA WT, wild-type CALM-AF10.
viral infection (Fig. 1e). These results indicate that NES1 is not sufficient, but its flanking regions including leucine-540 are necessary for cytoplasmic localization of CALM-AF10. Thus, we concluded that the NES2 region is the minimal NES that mediates cytoplasmic localization of CALM-AF10.

**The nuclear export signal within CALM is necessary for CALM-AF10-induced immortalization of cells in vitro.** We next investigated whether the NES within CALM-AF10 is required for leukemogenesis. To this end, primary murine bone-marrow stem/progenitor cells (HSPC) were infected with retrovirus encoding CALM-AF10, CALMNES4A-AF10, NES2-AF10 and mAF10. Serial-replating assays revealed that both CALM-AF10 and NES2-AF10 immortalized HSPC, and that the cells formed colonies for at least five rounds of replating (Fig. 2a). By contrast, neither mAF10 nor CALMNES4A-AF10, which lacks a functional CALM NES, could immortalize cells. Transduced cells with elevated colony-forming abilities also exhibited upregulation of the Hoxa cluster (Hoxa5, Hoxa7, Hoxa9 and Hoxa10) and Meis1 genes (Fig. 2b)(7,9). These results indicated that the CALM NES is necessary for CALM-AF10 to immortalize hematopoietic stem/progenitor cells.

**The nuclear export signal within CALM-AF10 is necessary to induce leukemia in vivo.** To determine whether CALM-AF10 and NES2-AF10 can induce leukemia in mice, we injected bone-marrow progenitor cells transduced with CALM-AF10 and NES2-AF10 into lethally irradiated mice. Seven out of eight mice transplanted with cells expressing CALM-AF10 developed leukemia within 6 months after transplantation (Fig. 3a), and all mice transplanted with cells expressing NES2-AF10 developed leukemia within 3 months after transplantation. When cells prepared from bone marrow of these leukemic mice were transplanted into secondary recipient mice, all recipients promptly developed leukemia (medians: CALM-AF10 donors, 21 days [n = 4]; NES2-AF10 donors,
Morphological analysis revealed large populations of blast cells in leukemic mice receiving cells transduced with either CALM-AF10 or NES2-AF10 (Fig. 3b, c). Flow cytometric analysis showed that cells expressing CALM-AF10 and NES2-AF10 in the bone marrow cells of primary recipient mice were Mac1⁺, CSF1R⁺ and c-kit⁺ (Fig. 4a). Moreover, as shown in Figure 4b, Hoxa5, Hoxa7, Hoxa9, Hoxa10 and Meis1 expression levels were upregulated in cells expressing CALM-AF10 and NES2-AF10 compared with normal bone marrow cells, although upregulation of Hoxa5 and Meis1 in primary recipient mice harboring NES2-AF10 was not significant (P = 0.084 and P = 0.093, respectively). These...
Fig. 5. Dot1L mainly localize in the nucleus in CALM-AF10-induced or NES2-AF10-induced leukemic cells. (a) Subcellular distribution of endogenous Dot1L in CALM-AF10-induced or NES2-AF10-induced leukemic cells. Cytospins of the cells were stained with anti-FLAG antibody (red), anti-Dot1L antibody (green) and DAPI (blue) and observed by confocal laser scanning microscopy. Note that GFP expression was not detected in the condition. (b) Subcellular distribution of endogenous Dot1L in the control vector-infected murine using fluorescence microscopy. (c) Population of leukemia cells expressing Dot1L and CALM-AF10 or FLAG-NES2-AF10 in the nucleus and the cytoplasm shown in (a) and (b). The scale bar represents 5 μm in (a) and 10 μm in (b).
data demonstrate that the NES within CALM-AF10 is a critical element for induction of leukemia.

It has been reported that CALM-AF10 interacts with the histone methyltransferase DOT1L to mediate H3K79 hypermethylation at the Hoxa5 locus.(9) To determine whether Dot1L colocalizes with CALM-AF10 and NES2-AF10 in the leukemia cells, we performed immunofluorescence analysis. DOT1L mainly localized in the nucleus while CALM-AF10 and NES2-AF10 mainly localized in the cytoplasm (Fig. 5a,b). DOT1L partially colocalized with both CALM-AF10 and NES2-AF10, but neither CALM-AF10 nor NES2-AF10 altered the localization of Dot1L (Fig. 5a).

Discussion

AF10 and CALM localize diffusely in the nucleus and cytoplasm, respectively, whereas CALM-AF10 primarily localizes in cytoplasmic speckle domains (see Fig. 1.c,d). The fact that CALM-AF10 regulates histone methylation at the Hoxa5 locus suggests that CALM-AF10 is likely to function in the nucleus. However, the results described here indicate that the CALM NES is essential for CALM-AF10-induced leukemogenesis, suggesting that cytoplasmic localization (or shuttling between nucleus and cytoplasm) is critical for the function of CALM-AF10. During the preparation of the manuscript, another group reported similar findings,(19) indicating that the results are reproducible and the conclusions can be validated using alternative experimental systems.

The molecular mechanism by which CALM-AF10 exerts its function in the cytoplasm remains unclear, but two possibilities are consistent with the existing data: CALM-AF10 may affect cytoplasmic signaling pathways that regulate expression of its target genes, including HoxA cluster genes; alternatively, CALM-AF10 may affect the functions of transcriptional regulators by changing their localization from the nucleus to the cytoplasm. DOT1L, a candidate mediator of CALM-AF10-induced leukemogenesis, interacts with AF10 and induces H3K79 hypermethylation at Hoxa5.(9) However, our present data suggest that CALM-AF10 and NES2-AF10 did not affect the localization of Dot1L (see Fig. 5a). It is possible that CALM-AF10 squelches DOT1L inhibitors by exporting them to the cytoplasm.

CALM plays an important role in clathrin-mediated endocytosis.(17,20,21) It and other endocytosis-related genes, such as EPS15, EEN, CLTC and HIP1, are involved in multiple types of leukemia-associated chromosomal translocations (e.g. MLL-CALM, MLL-EPS15, MLL-EEN, CLTC-ALK and HIP1-PDGFB), suggesting that these leukemia-associated fusions might affect endocytosis in a manner that contributes to leukemogenesis. However, recent reports have shown that the clathrin-binding domain of CALM is not essential for CALM-AF10-mediated leukemogenesis. Here, we show that nuclear export of CALM-AF10 is critical for the leukemogenesis. Because the endocytosis-related proteins mentioned above are also exported from the nucleus to the cytoplasm, as in the case of CALM,(11,23,29) it is possible that changes in the localization of fusions involving endocytosis-related proteins have some shared consequence that is important for leukemogenesis.

Molecular exchange between the nucleus and cytoplasm takes place through nuclear pore complexes (NPC). Fusion proteins containing NUP98 and NUP214, which are components of the NPC, have been found in AML and T-ALL,(30,31) and cells expressing CALM-AF10, a set of Hoxa and Meis1 genes are upregulated in leukemia cells expressing these NUP98 fusions and NUP214 fusions.(32,33) In addition, the NPC-component fusions interact with CRM1, the major receptor for the nuclear export of protein.(33,34) These observations suggest that alteration of the localization of certain factors by NUP98 fusions and NUP214 fusions might be important for leukemogenesis, and that a common mechanism may underlie leukemias induced by CALM and NUP fusions.

Acknowledgments

We thank Dr Y. Zhang for pcDNA3-FLAG-CALM-AF10 plasmid. This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Health, Labor, and Welfare and from the Ministry of Education, Culture, Sports, Science, and Technology; the National Cancer Center Research and Development Fund; the Naito Foundation; Cosmetology Research Foundation; and Nara Women’s University Intramural Grant for Project Research. MS is a Research Fellow for Yong Scientist of Japan Society for the Promotion of Science.

Disclosure Statement

The authors have no conflict of interest.

References

1 Dreyling MH, Martinez-Climent JA, Zheng M, Mao J, Rowley JD, Bohlander SK. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AF-3 clathrin assembly protein family. Proc Natl Acad Sci USA 1996; 93: 4804–9.

2 Bohlander SK, Muschinsky V, Schrader K et al. Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, T-ALL, and acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia 2000; 14: 93–9.

3 Narita M, Shimizu K, Hayashi Y et al. Consistent detection of CALM-AF10 chimaeric transcripts in haematological malignancies with t(10;11) (p13;q14) and identification of novel transcripts. Br J Haematol 1999; 105: 928–37.

4 Linder B, Newman R, Jones LK et al. Biochemical analyses of the AF10 protein: the extended LAP/PHD-finger mediates oligomerisation. J Mol Biol 2000; 299: 369–78.

5 Wysocka J, Swigut T, Xiao H et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 2006; 442: 86–90.

6 Greif PA, Tizazu B, Krause A, Kremmer E, Bohlander SK. The leukemogenic CALM/AF10 fusion protein alters the subcellular localization of the lyphoid regulator Ikaros. Oncogene 2008; 27: 2886–96.

7 Caudell D, Zhang Z, Chung YJ, Aplan PD. Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice. Cancer Res 2007; 67: 8022–31.

8 Mulaw MA, Krause A, Deshpande AJ et al. CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12. Leukemia 2012; 26: 1012–9.

9 Okada Y, Jiang Q, Lenieux M, Jeannotte L, Su L, Zhang Y. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by DOT1L. Nat Cell Biol 2006; 8: 1017–24.

10 Chen L, Deshpande AJ, Banka D et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1L. Leukemia 2013; 27: 813–22.

11 Vecchi M, Polo S, Poupon V, van de Loo JW, Benmerah A, Di Fiore PP. Nucleocytoplasmic shuttling of endocytic proteins. J Cell Biol 2001; 153: 1511–7.

12 Borkhardt A, Haas OA, Strobl W et al. A novel type of MLL-AF10 fusion transcript in a child with acute megakaryocytic leukemia (AML-M7). Leukemia 1995; 9: 1796–7.

13 Brandimarte L, Pierini V, Di Giacomo D et al. New MLLT10 gene recombination in pediatric T-acute lymphoblastic leukemia. Blood 2013; 121: 5064–7.
Lee JW, Liao PC, Young KC et al. Identification of hnRNPH1, NF45, and C14orf166 as novel host interacting partners of the mature hepatitis C virus core protein. J Proteome Res 2011; 10: 4522–34.

Ennas MG, Sorio C, Greim R et al. The human ALL-1/MLL/HRX antigen is predominantly localized in the nucleus of resting and proliferating peripheral blood mononuclear cells. Cancer Res 1997; 57: 2035–41.

Yedavalli VSRK, Neuveut C, Chi YH, Kleiman L, Jeang KT. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 2004; 119: 381–92.

Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 2001; 12: 2687–702.

Takagi M, Nishioka M, Kakihara H et al. Characterization of DNA polymerase from Pyrococcus sp. strain KOD1 and its application to PCR. Appl Environ Microbiol 1997; 63: 4504–10.

Conway AE, Scotland PB, Lavau CP, Wechsler DS. A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis. Blood 2013; 121: 4758–68.

Ford MGJ, Pearse BMF, Higgins MK, et al. Simultaneous binding of PtdIns(4,5)P₂ and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science 2001; 291: 1051–5.

Meyerholz A, Hinrichsen L, Groos S, Esk PC, Brandes G, Ungewickell EJ. Effect of clathrin assembly lymphoid myeloid leukemia protein depletion on clathrin coat formation. Traffic 2005; 6: 1225–34.

Bernard OA, Mauchauffe M, Mecucci C, Vandenberghe H, Berger R. A novel gene, Af-1p, fused to Hrx in T(1,11)(P32, Q23), is not related to Af-4, Af-9 nor Enl. Oncogene 1994; 9: 1039-45.

So CW, So CKC, Cheung N, Chew SL, Sham MH, Chan LC. The interaction between EEN and Abi-1, two MLL fusion partners, and synaptojanin and dynamin: implications for leukaemogenesis. Leukemia 2000; 14: 594–601.

Bridge JA, Kanamori M, Ma ZG et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001; 159: 411–5.

Wechsler DS, Engstrom LD, Alexander BM, Motto DG, Roulston D. A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein. Genes Chromosom Cancer 2003; 36: 26–36.

Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGF beta R) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 1998; 91: 4419–26.

Deshpande AJ, Rouhi A, Lin Y et al. The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia 2011; 25: 1718–27.

Stoddart A, Tennant TR, Fernald AA, Anastasi J, Brodsky FM, Le Beau MM. The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice. Oncogene 2012; 31: 494–506.

Engegyst-Goldstein AEY, Kessels MM, Chopra VS, Hayden MR, Drubin DG. An actin-binding protein of the Sla2/Huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles. J Cell Biol 1999; 147: 1503–18.

von Lindern M, Breems D, van Baal S, Adriaansen H, Grosveld G. Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosom Cancer 1992; 5: 227–34.

Nakamura T, Largaespada DA, Lee MP et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 1996; 12: 154–8.

Nakamura T. NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins. Int J Hematol 2005; 82: 21–7.

Van Vlierberghe P, van Grotel M, Tchinda J et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008; 111: 4668–80.

Takeda A, Sarma NJ, Abdul-Nabi AM, Yaseen NR. Inhibition of CRM1-mediated nuclear export of transcription factors by leukemogenic NUP98 fusion proteins. J Biol Chem 2010; 285: 16248–57.